Labetuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Labetuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target carcinoembryonic antigen
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 NYesY (what is this?)  (verify)

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]

This drug was developed by Immunomedics, Inc.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.
  2. ^ http://www.cancer.gov/drugdictionary?cdrid=692828